Aristotle Bamias

80 Vasilisis Sofias Avenue
Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Pancreatic Metastases from Urothelial Cancer.

Pancreatic Metastases from Urothelial Cancer.

Journal: European journal of case reports in internal medicine

Published: September 01, 2025

Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.

Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.

Journal: The oncologist

Published: July 19, 2025

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

Journal: ESMO open

Published: July 11, 2025

Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.

Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.

Journal: European urology

Published: July 30, 2024

Current role of PSMA-PET imaging in the clinical management of prostate cancer.

Current role of PSMA-PET imaging in the clinical management of prostate cancer.

Journal: Therapeutic advances in medical oncology

Published: June 04, 2023

Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.

Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.

Journal: European urology

Published: March 01, 2023

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.

Journal: Journal for immunotherapy of cancer

Published: December 23, 2022

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

Journal: ESMO open

Published: January 25, 2021

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250].

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250].

Journal: European urology

Published: May 25, 2020

Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity.

Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity.

Journal: Diabetes research and clinical practice

Published: May 21, 2020

Combination immunotherapy in metastatic urothelial cancer: time for the next step?

Combination immunotherapy in metastatic urothelial cancer: time for the next step?

Journal: Chinese clinical oncology

Published: October 25, 2019

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 29, 2019

Showing 1-12 of 76

Last Updated: 09/26/2026